Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial

Ryoji Ichijima, Hisatomo Ikehara, Daisuke Yamaguchi, Yasuhiko Nagata, Kanako Ogura, Mitsuru Esaki, Yosuke Minoda, Hiroyuki Ono, Yuki Maeda, Shinsuke Kiriyama, Tetsuya Sumiyoshi, Yuichi Kanmura, Takuji Gotoda

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Objectives: To assess the effectiveness of remimazolam against normal saline (placebo) as a sedative agent for endoscopy in a multicenter, randomized, double-blind, investigator-initiated phase III controlled trial. Methods: We included 48 Japanese patients undergoing upper gastrointestinal endoscopy. For the procedure, an initial remimazolam dose of 3 mg and additional doses of 1 mg were administered, as determined in the phase II clinical study. The primary study end-point was the successful sedation rate during gastrointestinal endoscopy, determined as a Modified Observer's Assessment of Alertness/Sedation score ≤4 before the start of endoscopy, the completion of gastrointestinal endoscopy, and two or fewer additional doses per 6 min. Results: The successful endoscopy sedation rates were 91.9% and 9.1% in the remimazolam and placebo groups, respectively (P < 0.01). The time from the end of endoscopy to arousal was 0.0 (0.0–0.0) min for both groups. The number of additional doses required to achieve sedation was lower in the remimazolam group than that in the placebo group (P < 0.01). Conclusions: Remimazolam demonstrated a significantly higher sedation effect during upper gastrointestinal endoscopy in Japanese patients with safe and fast recovery compared with placebo.

Original languageEnglish
JournalDigestive Endoscopy
DOIs
Publication statusAccepted/In press - 2024

Keywords

  • benzodiazepine drug
  • gastrointestinal endoscopy
  • placebo
  • remimazolam
  • sedative

Fingerprint

Dive into the research topics of 'Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial'. Together they form a unique fingerprint.

Cite this